Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365329 | 0.89 | HDAC3 (0.55) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL1366962 | 0.87 | HDAC1 (0.53) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL11962948 | 0.87 | HDAC1 (0.53) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL1366260 | 0.87 | HDAC1 (0.51) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL17425291 | 0.87 | HDAC1 (0.51) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL7953734 | 0.87 | HDAC1 (0.51) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL16302073 | 0.86 | HDAC1 (0.55) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL1367142 | 0.86 | HDAC3 (0.48) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL16459163 | 0.85 | HDAC1 (0.47) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL1364639 | 0.85 | HDAC1 (0.53) | HDAC1HDAC6HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | claimed |
| WO-2009137503-A1 | HDAC INHIBITORS AND USES THEREOF | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | claimed |
| EP-2049483-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2009-04-22 | — | — | EP | claimed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | claimed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2343286-B1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | METHYLGENE INC (CA) | 2014-12-31 | — | — | EP | disclosed |
| US-20140179678-A1 | METHODS OF TARGETED TREATMENT OF FRONTOTEMPORAL LOBAR DEGENERATION | FMR LLC | 2014-06-26 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| WO-2009137503-A1 | HDAC INHIBITORS AND USES THEREOF | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-2049483-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2009-04-22 | — | — | EP | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | HDAC1 1/4885HDAC6 9/4885HDAC3 14/4885 |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | HDAC1 1/4885HDAC6 11/4885HDAC3 4/4885 |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | HDAC1 1/4885HDAC6 9/4885HDAC3 14/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | HDAC1 3/4885HDAC6 11/4885HDAC3 15/4885 |
| US-20140179678-A1 | METHODS OF TARGETED TREATMENT OF FRONTOTEMPORAL LOBAR DEGENERATION | GRN, PRPH, TDP2 | HDAC1 4017/4885HDAC6 317/4885HDAC3 3574/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | HDAC1 1/4885HDAC6 9/4885HDAC3 7/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | HDAC1 1/4885HDAC6 11/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.